OBJECTIVE: To probe into the clinical of Xuanfei Tongluo formula in the treatment of children with Mycoplasma pneumoniae pneumonia（MPP）. METHODS: A total of 90 children with MPP admitted into the department of pediatrics of the hospital from Jan. 2020 to Mar. 2022 were extracted to be divided into the treatment group and control group via the random number table method

with 45 cases in each group. The control group was treated with conventional western medicine

including oxygen inhalation

atomization inhalation

liquid supplement

and azithromycin sequential therapy. The treatment group received Xuanfei Tongluo formula on the basis of the control group

and the course of treatment was 2 weeks. Before and after treatment

the traditional Chinese medicine syndrome score

pulmonary function indicators [maximum expiratory volume at one second（FEV

1

）

peak expiratory flow（PEF）

forced vital capacity（FVC）

FEV

1

/FVC]

the contents of serum nicotinamide phosphoribosyltransferase（NAMPT）

human cartilage glycoprotein 39（YKL-40）

interleukin-8（IL-8）

salivary secretory immunoglobulin A（sIgA） and human β-defensin 2（hBD2） and fecal calprotectin（CAL） of two groups were compared. The total effective rate and incidence of adverse drug reactions were compared between two groups. RESULTS: After treatment

the scores of cough

wheezing

cyanosis and fever in the treatment group were lower than those in the control group（P

<

0.01）

FEV

1

PEF and FEV

1

/FVC were higher than those in the control group（P

<

0.01）

and the serum levels of NAMPT

YKL-40 and IL-8 were lower than those in the control group（P

<

0.01）

the salivary sIgA was significantly higher than that in the control group（P

<

0.01）

and the salivary hBD2 and fecal CAL were significantly lower than those in the control group（P

<

0.01）

with statistically significant differences. The total effective rate of the treatment group was 95.56%（43/45）

higher than 82.22%（37/45） of the control group

the difference was statistically significant（P

<

0.05）. The incidence of adverse drug reactions in the treatment group was 6.67%（3/45）

lower than 22.22%（10/45） in the control group

the difference was statistically significant（P

<

0.05）. CONCLUSIONS: Xuanfei Tongluo formula can reduce the traditional Chinese medicine syndrome score of children

improve lung function and airway immune function

inhibit the expression of inflammatory factors

reduce salivary hBD2 and fecal CAL

and has significant effects on MPP.